Q&As with OCRF Researchers

Q&A with Tsz-Lun Yeung, Ph.D.

Dr. Tsz-Lun Yeung, Ph.D. is a 2011 Ann Schreiber Program of Excellence Grant Recipient. Sarah DeFeo: You were educated in Hong Kong. How did you end up doing research at MD Anderson Cancer Center in Houston? Tsz-Lun Yeung: I became interested in science in high school, and then studied molecular biology... 

Q&A with Sarah Adams, M.D., 2011 Liz Tilberis Awardee

Dr. Sarah Adams is a 2011 Liz Tilberis Grant Recipient. Sarah DeFeo: How did you end up becoming a gynecologic oncologist? Sarah Adams: Like many people, I didn’t always know this is what I wanted to do.  After college, I did volunteer work with AmeriCorps.  I was committed to service, and became... 

2011 SGO News: GI Risk Clarified for Bevacizumab

Ovarian cancer patients had a twofold greater risk of gastrointestinal adverse effects when bevacizumab was added to chemotherapy, but the angiogenesis inhibitor did not exacerbate other known risks for GI events, data from a large prospective trial showed. Treatment with bevacizumab was associated...